Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Castle Biosciences' bullish structure is strengthening as momentum builds ahead of a possible breakout.
BTIG analyst Mark Massaro maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and raises the price target from $32 to $38.
Baird analyst Catherine Ramsey maintains Castle Biosciences (NASDAQ:CSTL) with a Outperform and raises the price target from...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today ann...
Castle Biosciences (NASDAQ:CSTL) raises FY2025 sales outlook from $310.000 million-$320.000 million to $327.000 million-$335.00...
Castle Biosciences (NASDAQ:CSTL) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(...
